Showing results (31-40 of 42) with videos related to
Sort By:
Pageof 5
Lung Cancer (Amsterdam, Netherlands)|April 28, 2019
Trends in response rate and survival in small-cell lung cancer patients between 1997 and 2017Mickaël Lattuca-Truc, Jean-François Timsit, Matteo Giaj Levra, et al.Cancer Treatment and Research Communications|January 16, 2022
Survival of clinical stage III NSCLC according to therapeutic strategy: Relevance of the tumor board decision in the era of immunotherapyJustin Benet, Anne-Claire Toffart, Pierre-Yves Brichon, et al.Molecular Oncology|May 20, 2022
Altered splicing of ATG16-L1 mediates acquired resistance to tyrosine kinase inhibitors of EGFR by blocking autophagy in non-small cell lung cancerAnne-Sophie Hatat, Clara Benoit-Pilven, Amélie Pucciarelli, et al.European Journal of Cancer (Oxford, England : 1990)|October 27, 2019
Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinionLizza E L Hendriks, Christophe Dooms, Thierry Berghmans, et al.Lung Cancer (Amsterdam, Netherlands)|February 20, 2022
Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancersAnne Mc Leer, Matthieu Foll, Marie Brevet, et al.Cancer|November 3, 2011
Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomasAntoine Italiano, Angela Cioffi, Nicolas Penel, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 16, 2018
A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic CharacteristicsLéonie Ferrer, Matteo Giaj Levra, Marie Brevet, et al.Lung Cancer (Amsterdam, Netherlands)|February 8, 2018
ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancerAnne McLeer-Florin, Michael Duruisseaux, Julian Pinsolle, et al.The Lancet. Oncology|May 17, 2014
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trialVanesa Gregorc, Silvia Novello, Chiara Lazzari, et al.Lung Cancer (Amsterdam, Netherlands)|June 12, 2022
Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) surveySara Pilotto, Alice Avancini, Jessica Menis, et al.Pageof 5